Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 5/20 | 0.60 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 9/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423035 | 0.91 | ACLY (0.53) | APLNRCXCR3CNR2TAS2R14NFE2L2 | |
| SCHEMBL30684179 | 0.85 | APLNR (0.52) | APLNRCXCR3CNR2TAS2R14PTGES | |
| SCHEMBL20618408 | 0.85 | APLNR (0.52) | APLNRCXCR3CNR2TAS2R14PTGES | |
| SCHEMBL31149221 | 0.84 | APLNR (0.54) | APLNRCXCR3CNR2TAS2R14PTGES | |
| SCHEMBL31149209 | 0.84 | APLNR (0.54) | APLNRCXCR3CNR2TAS2R14PTGES | |
| SCHEMBL20474629 | 0.84 | APLNR (0.54) | APLNRCXCR3CNR2TAS2R14PTGES | |
| SCHEMBL20474627 | 0.82 | APLNR (0.51) | APLNRCXCR3CNR2TAS2R14PTGES | |
| SCHEMBL20609788 | 0.78 | APLNR (0.54) | APLNRCXCR3CNR2TAS2R14PTGES | |
| SCHEMBL426700 | 0.77 | LMNA (0.57) | APLNRNFE2L2CNR1 | |
| SCHEMBL29850423 | 0.77 | ALDH1A1 (0.69) | APLNRCXCR3CNR2TAS2R14PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | APLNR 3127/4885CXCR3 2765/4885CNR2 745/4885 |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | APLNR 3127/4885CXCR3 2765/4885CNR2 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.